Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers April 24, 2017
Pharmacy Choice - Pharmaceutical News - Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen? - April 24, 2017

Pharmacy News Article

 3/20/17 - Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen?

By a News Reporter-Staff News Editor at Pharma Business Week Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the "Company") announced that the Pediatric Committee ("PDCO") of the European Medicines Agency ("EMA") agreed to the Company's Pediatric Investigation Plan ("PIP") for Macrilen? and agreed that the Company may defer conducting the PIP until after it files a Marketing Authorization Application ("MAA") seeking marketing authorization for the use of Macrilen? for the evaluation of adult growth hormone deficiency (see also Pharmaceutical Companies).

As part of the regulatory process for the registration of new medicines in Europe, pharmaceutical companies are required to provide a PIP outlining their strategy for investigation of the new medicinal product in the pediatric population. An accepted PIP is a prerequisite for filing an MAA for any new medicinal product in Europe. However, the Company will be able to file an MAA substantially earlier than if it was required to complete the PIP before filing, because the PDCO permitted the Company to defer conducting the studies defined in the PIP.

The Company's PIP provides for a dose-escalation safety and PK/PD study followed by a diagnostic efficacy and safety study. The goal of the first study is to establish a dose that can safely be administered to pediatric patients and that causes a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having growth hormone deficiency ("GHD"). The recommended dose derived from this study will be evaluated in the second study for diagnostic efficacy and safety. Both studies will be conducted in patients at least three years old who are undergoing the study sites' regular diagnostic evaluation for the presence of GHD.

Keywords for this news article include: Pharmaceutical Companies, Marketing, Pediatrics, Advertising, Endocrinology, Peptide Hormones, Aeterna Zentaris Inc., Growth Hormone Deficiency, Anterior Pituitary Hormones.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Apr 25: Skin Infections: Focus on Cellulitis & MRSA
Last Chance
Apr 26: Medical Marijuana: Examining the Science, Not the Politics
Apr 27: What's New? New Treatments for Type 2 Diabetes
Apr 30: Using Effective Communication to Reduce Medication Errors
May 01: The New Hypertension Guidelines: What are They Telling Us?
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement